Top

Discover Oncology

Published in:

Open Access 01-12-2024 | Acute Myeloid Leukemia | Analysis

T cell-mediated tumor killing sensitivity gene signature-based prognostic score for acute myeloid leukemia

Authors: Yiyun Pan, FangFang Xie, Wen Zeng, Hailong Chen, Zhengcong Chen, Dechang Xu, Yijian Chen

Published in: Discover Oncology | Issue 1/2024

Abstract

Background and Objective

Acute myeloid leukemia (AML) is an aggressive, heterogenous hematopoetic malignancies with poor long-term prognosis. T-cell mediated tumor killing plays a key role in tumor immunity. Here, we explored the prognostic performance and functional significance of a T-cell mediated tumor killing sensitivity gene (GSTTK)-based prognostic score (TTKPI).

Methods

Publicly available transcriptomic data for AML were obtained from TCGA and NCBI-GEO. GSTTK were identified from the TISIDB database. Signature GSTTK for AML were identified by differential expression analysis, COX proportional hazards and LASSO regression analysis and a comprehensive TTKPI score was constructed. Prognostic performance of the TTKPI was examined using Kaplan–Meier survival analysis, Receiver operating curves, and nomogram analysis. Association of TTKPI with clinical phenotypes, tumor immune cell infiltration patterns, checkpoint expression patterns were analysed. Drug docking was used to identify important candidate drugs based on the TTKPI-component genes.

Results

From 401 differentially expressed GSTTK in AML, 24 genes were identified as signature genes and used to construct the TTKPI score. High-TTKPI risk score predicted worse survival and good prognostic accuracy with AUC values ranging from 75 to 96%. Higher TTKPI scores were associated with older age and cancer stage, which showed improved prognostic performance when combined with TTKPI. High TTKPI was associated with lower naïve CD4 T cell and follicular helper T cell infiltrates and higher M2 macrophages/monocyte infiltration. Distinct patterns of immune checkpoint expression corresponded with TTKPI score groups. Three agents; DB11791 (Capmatinib), DB12886 (GSK-1521498) and DB14773 (Lifirafenib) were identified as candidates for AML.

Conclusion

A T-cell mediated killing sensitivity gene-based prognostic score TTKPI showed good accuracy in predicting survival in AML. TTKPI corresponded to functional and immunological features of the tumor microenvironment including checkpoint expression patterns and should be investigated for precision medicine approaches.

Available only for authorised users

Systematic Literature Review of the Global Incidence and Prevalence of Myelodysplastic Syndrome and Acute Myeloid Leukemia | Semantic Scholar. https://www.semanticscholar.org/paper/Systematic-Literature-Review-of-the-Global-and-of-Lubeck-Danese/3618fb1ed8a1d9cf79c1d3731ba24dc48b04d1d7

The Global Incidence And Prevalence Of Acute Myeloid Leukemia Over The Next Ten Years (2017–2027). | Journal of Cancer Research & Therapeutics | EBSCOhost. https://openurl.ebsco.com/EPDB%3Agcd%3A3%3A53859/detailv2?sid=ebsco%3Aplink%3Ascholar&id=ebsco%3Agcd%3A127250837&crl=c

Strom SS, Oum R, Elhor Gbito KY, Garcia-Manero G, Yamamura Y. De novo acute myeloid leukemia risk factors: a Texas case-control study. Cancer. 2012;118(18):4589–96.PubMedCrossRef

Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States - PubMed]. https://pubmed.ncbi.nlm.nih.gov/30268525/

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood J Am Soc Hematol. 2017;129(4):424–47.

Outcomes and health care utilization of older patients with acute myeloid leukemia – PubMed. https://pubmed.ncbi.nlm.nih.gov/32713804/

Mohamed Jiffry MZ, Kloss R, Ahmed-Khan M, Carmona-Pires F, Okam N, Weeraddana P, et al. A review of treatment options employed in relapsed/refractory AML. Hematol Amst Neth. 2023;28(1):2196482.

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77.PubMedCrossRef

Stein EM. IDH inhibitors in acute myeloid leukemia and myelodysplastic syndrome. Clin Adv Hematol Oncol HO. 2021;19(9):556–8.

10.

A review of FLT3 inhibitors in acute myeloid leukemia – PubMed. https://pubmed.ncbi.nlm.nih.gov/34774343/

11.

Stomper J, Rotondo JC, Greve G, Lübbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35(7):1873–89.PubMedPubMedCentralCrossRef

12.

Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C. Subtype-specific patterns of molecular mutations in acute myeloid leukemia. Leukemia. 2017;31(1):11–7.PubMedCrossRef

13.

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–98.PubMedCrossRef

14.

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia – PubMed. https://pubmed.ncbi.nlm.nih.gov/35443108/

15.

Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–31.PubMedPubMedCentralCrossRef

16.

Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O’Connell CL, Tibes R, et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017;18(10):1317–26.PubMedPubMedCentralCrossRef

17.

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission – PubMed. https://pubmed.ncbi.nlm.nih.gov/33369355/

18.

Nixdorf D, Sponheimer M, Berghammer D, Engert F, Bader U, Philipp N, et al. Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML. Leukemia. 2023;37(6):1298–310.PubMedPubMedCentralCrossRef

19.

Kasakovski D, Xu L, Li Y. T cell senescence and CAR-T cell exhaustion in hematological malignancies. J Hematol Oncol. 2018;11(1):91.PubMedPubMedCentralCrossRef

20.

Lamble AJ, Kosaka Y, Laderas T, Maffit A, Kaempf A, Brady LK, et al. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. Proc Natl Acad Sci USA. 2020;117(25):14331–41.PubMedPubMedCentralCrossRef

21.

Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019;25(4):603–11.PubMedCrossRef

22.

Fiorenza S, Turtle CJ. CAR-T cell therapy for acute myeloid leukemia: preclinical rationale, current clinical progress, and barriers to success. BioDrugs Clin Immunother Biopharm Gene Ther. 2021;35(3):281–302.

23.

Angenendt L, Mikesch JH, Schliemann C. Emerging antibody-based therapies for the treatment of acute myeloid leukemia. Cancer Treat Rev. 2022;108:102409.PubMedCrossRef

24.

Daver N, Alotaibi AS, Bücklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35(7):1843–63.PubMedPubMedCentralCrossRef

25.

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer – PubMed. https://pubmed.ncbi.nlm.nih.gov/35707528/

26.

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia – PubMed. https://pubmed.ncbi.nlm.nih.gov/30500073/

27.

Huang J, Tan J, Chen Y, Huang S, Xu L, Zhang Y, et al. A skewed distribution and increased PD-1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia. J Leukoc Biol. 2019;106(3):725–32.PubMedCrossRef

28.

Vadakekolathu J, Rutella S. Escape from T-cell targeting immunotherapies in acute myeloid leukemia. Blood. 2023. https://doi.org/10.1182/blood.2023019961.CrossRefPubMed

29.

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy – PubMed. https://pubmed.ncbi.nlm.nih.gov/34663807/

30.

Nieuwenhuis TO, Yang SY, Verma RX, Pillalamarri V, Arking DE, Rosenberg AZ, et al. Consistent RNA sequencing contamination in GTEx and other data sets. Nat Commun. 2020;11(1):1933.PubMedPubMedCentralCrossRef

31.

Wang YH, Lin CC, Hsu CL, Hung SY, Yao CY, Lee SH, et al. Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125. Ann Hematol. 2021;100(2):487–98.PubMedCrossRef

32.

Chuang MK, Chiu YC, Chou WC, Hou HA, Tseng MH, Kuo YY, et al. An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype. Oncotarget. 2015;6(36):39098–110.PubMedPubMedCentralCrossRef

33.

Lee SH, Chiu YC, Li YH, Lin CC, Hou HA, Chou WC, et al. High expression of dedicator of cytokinesis 1 (DOCK1) confers poor prognosis in acute myeloid leukemia. Oncotarget. 2017;8(42):72250–9.PubMedPubMedCentralCrossRef

34.

Kuett A, Rieger C, Perathoner D, Herold T, Wagner M, Sironi S, et al. IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia. Sci Rep. 2015;17(5):18411.CrossRef

35.

Herold T, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Ksienzyk B, et al. A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia. Haematologica. 2018;103(3):456–65.PubMedPubMedCentralCrossRef

36.

Herold T, Metzeler KH, Vosberg S, Hartmann L, Röllig C, Stölzel F, et al. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood. 2014;124(8):1304–11.PubMedCrossRef

37.

Li Z, Herold T, He C, Valk PJM, Chen P, Jurinovic V, et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(9):1172–81.CrossRef

38.

The sva package for removing batch effects and other unwanted variation in high-throughput experiments – PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307112/

39.

Vexler A, Gao X, Zhou J. How to implement signed-rank wilcox test () type procedures when a center of symmetry is unknown. Comput Stat Data Anal. 2023;184:107746.CrossRef

40.

Team RC. R: a language and environment for statistical computing. Vienna: R Core team; 2021.

41.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021. https://doi.org/10.1016/j.xinn.2021.100141.CrossRefPubMedPubMedCentral

42.

Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638–46.PubMedCrossRef

43.

Legeay M, Doncheva NT, Morris JH, Jensen LJ. Visualize omics data on networks with Omics visualizer, a cytoscape app. F1000Research. 2020. https://doi.org/10.1268/f1000research.22280.1.CrossRefPubMedPubMedCentral

44.

Zeng Z, Gao Y, Li J, Zhang G, Sun S, Wu Q, et al. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts. Comput Struct Biotechnol J. 2022;20:496–507.PubMedPubMedCentralCrossRef

45.

Pawar A, Chowdhury OR, Salvi O. A narrative review of survival analysis in oncology using R. Cancer Res Stat Treat. 2022;5(3):554–61.CrossRef

46.

Friedman J, Hastie T, Tibshirani R, Narasimhan B, Tay K, Simon N, et al. Package ‘glmnet’. CRAN R Repositary. http://r.meteo.uni.wroc.pl/web/packages/glmnet/glmnet.pdf

47.

Qiao T, Yin B, Liang J, Wei L. Implications of T cell-mediated tumor killing genes for molecular heterogeneity and clinical stratification in lung adenocarcinoma. Genes Dis. 2024;11(4):101162.PubMedCrossRef

48.

Feng HW, Yuan LM, Liang L, Suo DuS, Jie CY, Heng ML. Molecular characteristics of T cell-mediated tumor killing in hepatocellular carcinoma. Front Immunol. 2022;13:868480.CrossRef

49.

Hu S, Duan H, Lu Y, Huang S. The genes regulating sensitivity of tumor cells to T cell-mediated killing: could they be potential personalized immunotherapeutic targets in head and neck squamous cell carcinoma? Discov Oncol. 2023;14(1):199.PubMedPubMedCentralCrossRef

50.

ChAMP: updated methylation analysis pipeline for Illumina BeadChips | Bioinformatics | Oxford Academic. https://academic.oup.com/bioinformatics/article/33/24/3982/4082274?login=false

51.

Skidmore ZL, Wagner AH, Lesurf R, Campbell KM, Kunisaki J, Griffith OL, et al. GenVisR: genomic visualizations in R. Bioinformatics. 2016;32(19):3012–4.PubMedPubMedCentralCrossRef

52.

Li ZM, Liu W, Chen XL, Wu WZ, Xu XE, Chu MY, et al. Construction and validation of classification models for predicting the response to concurrent chemo-radiotherapy of patients with esophageal squamous cell carcinoma based on multi-omics data. Clin Res Hepatol Gastroenterol. 2024. https://doi.org/10.1016/j.clinre.2024.102318.CrossRefPubMed

53.

Huang Y, Li W, Macheret F, Gabriel RA, Ohno-Machado L. A tutorial on calibration measurements and calibration models for clinical prediction models. J Am Med Inform Assoc. 2020;27(4):621–33.PubMedPubMedCentralCrossRef

54.

Mooers BHM. Shortcuts for faster image creation in PyMOL. Protein Sci. 2020;29(1):268–76.PubMedCrossRef

55.

Manavi MA. Identification of some Novel Racetams as Potential Anti-Convulsant Agents: Virtual Screening, Molecular Docking, and ADMET Study. 2022. https://biointerfaceresearch.com/wp-content/uploads/2023/01/BRIAC135.422.pdf

56.

Brück O, Dufva O, Hohtari H, Blom S, Turkki R, Ilander M, et al. Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. Blood Adv. 2020;4(2):274–86.PubMedPubMedCentralCrossRef

57.

The impact of age, NPM1mut, and FLT3ITD allelic ratio in patients with acute myeloid leukemia – PubMed. https://pubmed.ncbi.nlm.nih.gov/29183886/

58.

Xu L, Yao D, Tan J, He Z, Yu Z, Chen J, et al. Memory T cells skew toward terminal differentiation in the CD8+ T cell population in patients with acute myeloid leukemia. J Hematol Oncol. 2018;11(1):93.PubMedPubMedCentralCrossRef

59.

Gu Y, Qiang CM, Jun XZ, Yuan Q, Juan ZT, Lin J, et al. Comprehensive analysis of SPAG1 expression as a prognostic and predictive biomarker in acute myeloid leukemia by integrative bioinformatics and clinical validation. BMC Med Genomics. 2022;15(1):38.PubMedPubMedCentralCrossRef

60.

Lu LIU, Jing LIU, Xiao-Jun LIU, Meng-Han LIU, Xue-Feng F, Lin Y, et al. SPAG1 promotes the development of AML by activating the ERK/MAPK signaling pathway and affects the chemotherapy sensitivity of venetoclax. Neoplasma. 2022. https://doi.org/10.4149/neo_2022_220415N416.CrossRefPubMed

61.

Jiang F, Lang X, Chen N, Jin L, Liu L, Wei X, et al. A novel HNRNPH1::ERG rearrangement in aggressive acute myeloid leukemia. Genes Chromosom Cancer. 2022;61(8):503–8.PubMedCrossRef

62.

Rahn K, Abdallah AT, Gan L, Herbrich S, Sonntag R, Benitez O, et al. Insight into the mechanism of AML del (9q) progression: hnRNP K targets the myeloid master regulators CEBPA (C/EBPα) and SPI1 (PU 1). Biochim Biophys Acta BBA-Gene Regul Mech. 2024;1867(1):195004.CrossRef

63.

Wang C, He H, Liu G, Ma H, Li L, Jiang M, et al. DT-13 induced apoptosis and promoted differentiation of acute myeloid leukemia cells by activating AMPK-KLF2 pathway. Pharmacol Res. 2020;158:104864.PubMedCrossRef

64.

Meng Z, Zhu L, Liu W, Yang W, Wang Y. T cell-mediated tumor killing patterns in head and neck squamous cell carcinoma identify novel molecular subtypes, with prognosis and therapeutic implications. PLoS ONE. 2023;18(5):e0285832.PubMedPubMedCentralCrossRef

65.

Bi L, Ai C, Zhang H, Chen Z, Deng Y, Xiong J, et al. Prognostic characteristics of T-cell mediated cell killing-related genes in lung adenocarcinoma. Autoimmunity. 2023;56(1):2250097.PubMedCrossRef

66.

Perna F, Espinoza-Gutarra MR, Bombaci G, Farag SS, Schwartz JE. Immune-based therapeutic interventions for acute myeloid leukemia. In: Hays P, editor. Cancer immunotherapies. Cham: Springer International Publishing; 2022. p. 225–54.CrossRef

67.

Daver N. Immune checkpoint inhibitors in acute myeloid leukemia. Best Pract Res Clin Haematol. 2021;34(1):101247.PubMedCrossRef

68.

Ziogas DC, Theocharopoulos C, Lialios PP, Foteinou D, Koumprentziotis IA, Xynos G, et al. Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment. Cancers. 2023;15(10):2718.PubMedPubMedCentralCrossRef

69.

Zhong FM, Yao FY, Liu J, Zhang HB, Li MY, Jiang JY, et al. Inflammatory response mediates cross-talk with immune function and reveals clinical features in acute myeloid leukemia. 2022. Biosci Rep. https://doi.org/10.1042/BSR20220647.

70.

A 17-gene stemness score for rapid determination of risk in acute leukaemia | Nature. https://www.nature.com/articles/nature20598

71.

Docking TR, Parker JDK, Jädersten M, Duns G, Chang L, Jiang J, et al. A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia. Nat Commun. 2021;12(1):2474.PubMedPubMedCentralCrossRef

72.

Zhu R, Tao H, Lin W, Tang L, Hu Y. Identification of an immune-related gene signature based on immunogenomic landscape analysis to predict the prognosis of adult acute myeloid leukemia patients. Front Oncol. 2020. https://doi.org/10.3389/fonc.2020.574939/full.CrossRefPubMedPubMedCentral

73.

Lu C, Zhu J, Chen X, Hu Y, Xie W, Yao J, et al. Risk stratification in acute myeloid leukemia using CXCR gene signatures: a bioinformatics analysis. Front Oncol. 2020. https://doi.org/10.3389/fonc.2020.584766/full.CrossRefPubMedPubMedCentral

74.

Jiang F, Mao Y, Lu B, Zhou G, Wang J. A hypoxia risk signature for the tumor immune microenvironment evaluation and prognosis prediction in acute myeloid leukemia. Sci Rep. 2021;11(1):14657.PubMedPubMedCentralCrossRef

Title: T cell-mediated tumor killing sensitivity gene signature-based prognostic score for acute myeloid leukemia
Authors: Yiyun Pan
FangFang Xie
Wen Zeng
Hailong Chen
Zhengcong Chen
Dechang Xu
Yijian Chen
Publication date: 01-12-2024
Publisher: Springer US
Keyword: Acute Myeloid Leukemia
Published in: Discover Oncology / Issue 1/2024
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-024-00962-w

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background and Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Development of chitosan-folate modified PLGA nanoparticles for targeted delivery of diosgenin as an anticancer agent

Stratification and prognostic evaluation of breast cancer subtypes defined by obesity-associated genes

Analysis of factors related to osteoporotic vertebral fracture in prostate cancer patients

A combination of cuproptosis and lncRNAs predicts the prognosis and tumor immune microenvironment in cervical cancer

Significance and implications of FHIT gene expression and promoter hypermethylation in acute lymphoblastic leukemia (ALL)

Clinical research progress of callisperes® of drug-loaded microsphere arterial chemoembolisation in the treatment of solid tumors

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage